The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.

The present invention relates to the technical field of crop protection. More specifically, the present invention relates to benazolin-choline and to compositions (formulations) comprising benazolin-choline. The invention also relates to methods of manufacturing benazolin-choline and compositions comprising benazolin-choline as well as uses thereof.

The present invention relates to the technical field of crop protection. More specifically, the present invention relates to benazolin-choline and to compositions (formulations) comprising benazolin-choline. The invention also relates to methods of manufacturing benazolin-choline and compositions comprising benazolin-choline as well as uses thereof.

Disclosed herein are compounds that can be used to selectively detect nitric oxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting nitric oxide using the compounds.

Disclosed herein are compounds that can be used to selectively detect superoxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting superoxide using the compounds.

Disclosed herein are compounds that can be used to selectively detect superoxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting superoxide using the compounds.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

A polymerizable liquid crystal compound represented by the following general formula (1):

##STR00001##

(the symbols in the general formula (1) are as described in the DESCRIPTION.)

Luciferin-containing substrates are provided including a substrate and luciferin dried on the substrate. The luciferin-containing substrate is free of a detectable amount of reactive luciferase. The substrate is optionally a nonwoven substrate. Monitoring devices are also provided. The monitoring devices include a test element having a test portion, a detection reagent comprising luciferase, a luciferin-containing substrate, and a container having a first end with an opening and a second end opposite the first end. The container is configured to receive the test portion and configured to be operationally coupled to an analytical instrument. The detection reagent and the luciferin each are capable of participating in one or more chemical reaction that results in the formation of a detectable product.